Emerging drugs for the treatment of myelofibrosis

Bibliography

• Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-5
   PubMed Web of Science ®Google Scholar
• Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 1999;61:10-15
   PubMed Web of Science ®Google Scholar
• Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007;109:68-76
   PubMed Web of Science ®Google Scholar
• Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012;30:4098-103
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 2008;111:3383-7
   PubMed Web of Science ®Google Scholar
• Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23:2224-32
   PubMed Web of Science ®Google Scholar
• Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010;115:778-82
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392-7
   PubMed Web of Science ®Google Scholar
• Cervantes F, Tassies D, Salgado C, et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 1991;85:124-7
   PubMed Web of Science ®Google Scholar
• Okamura T, Kinukawa N, Niho Y, et al. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol 2001;73:194-8
   PubMed Web of Science ®Google Scholar
• Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005;105:973-7
   PubMed Web of Science ®Google Scholar
• Wang H, Mehta J, Iqbal U, et al. Analysis of the Impact and Burden of Illness of Myelofibrosis in the US [abstract 972]. Blood (ASH Annual Meeting Abstracts) 2012
   Google Scholar
• Mesa R, Miller CB, Thyne M, et al. Impact of myeloproliferative neoplasms (MPNs) on patients’ overall health and productivity: results from the MPN LANDMARK SURVEY in the United States. 56th ASH® Annual Meeting and Exposition; 6-9 December 2014; San Francisco CA; 2014
   Google Scholar
• Kerbauy DM, Gooley TA, Sale GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007;13:355-65
   PubMed Web of Science ®Google Scholar
• Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010;89:1233-7
   PubMed Web of Science ®Google Scholar
• Sirhan S, Lasho TL, Hanson CA, et al. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 2008;83:363-5
   PubMed Web of Science ®Google Scholar
• Santos FP, Tam CS, Kantarjian H, et al. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma 2014;55:121-7
   PubMed Web of Science ®Google Scholar
• Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001;92:1684-8
   PubMed Web of Science ®Google Scholar
• Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol 2001;115:619-21
   PubMed Web of Science ®Google Scholar
• Koch CA, Li CY, Mesa RA, et al. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc 2003;78:1223-33
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-901
   PubMed Web of Science ®Google Scholar
• Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009;27:4563-9
   PubMed Web of Science ®Google Scholar
• Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011;25:301-4
   PubMed Web of Science ®Google Scholar
• Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009;33:1199-203
   PubMed Web of Science ®Google Scholar
• Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011;118:401-8
   PubMed Web of Science ®Google Scholar
• Geyer HL, Emanuel RM, Dueck AC, et al. Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood 2014;123(24):3803-10
   PubMed Web of Science ®Google Scholar
• Geyer H, Dueck AC, Emanuel RM, et al. Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). Blood 2013;122:4087
   Google Scholar
• Geyer H, Dueck AC, Emanuel RM, et al. Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). Blood 2013;122:4088
   Google Scholar
• Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012;26:475-80
   PubMed Web of Science ®Google Scholar
• Groopman JE. The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann Intern Med 1980;92:857-8
   PubMed Web of Science ®Google Scholar
• Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Ruxolitinib-induced modulation of bone marrow microenvironment in patients with myelofibrosis is associated with inflammatory cytokine levels. 2014
   Google Scholar
• Wang JC, Chen C, Dumlao T, et al. Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leuk Lymphoma 2008;49:2321-7
   PubMed Web of Science ®Google Scholar
• Glozak MA, Sengupta N, Zhang X, et al. Acetylation and deacetylation of non-histone proteins. Gene 2005;363:15-23
   PubMed Web of Science ®Google Scholar
• Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010;28:605-13
   PubMed Web of Science ®Google Scholar
• Irvine DA, Copland M. Targeting hedgehog in hematologic malignancy. Blood 2012;119:2196-204
   PubMed Web of Science ®Google Scholar
• Lin TL, Matsui W. Hedgehog pathway as a drug target: Smoothened inhibitors in development. Onco Targets Ther 2012;5:47-58
   PubMed Web of Science ®Google Scholar
• Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008;410:439-53
   PubMed Web of Science ®Google Scholar
• Wang Y, Fiskus W, Chong DG, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009;114:5024-33
   PubMed Web of Science ®Google Scholar
• George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005;105:1768-76
   PubMed Web of Science ®Google Scholar
• Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978;51:189-94
   PubMed Web of Science ®Google Scholar
• Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23:8520-30
   PubMed Web of Science ®Google Scholar
• Kimura A, Katoh O, Kuramoto A. Effects of platelet derived growth factor, epidermal growth factor and transforming growth factor-beta on the growth of human marrow fibroblasts. Br J Haematol 1988;69:9-12
   PubMed Web of Science ®Google Scholar
• Bedekovics J, Kiss A, Beke L, et al. Platelet derived growth factor receptor-beta (PDGFRbeta) expression is limited to activated stromal cells in the bone marrow and shows a strong correlation with the grade of myelofibrosis. Virchows Arch 2013;463:57-65
   PubMed Web of Science ®Google Scholar
• Hodes R. Molecular targeting of cancer: telomeres as targets. Proc Natl Acad Sci U S A 2001;98:7649-51
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62
   PubMed Web of Science ®Google Scholar
• Katso R, Okkenhaug K, Ahmadi K, et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001;17:615-75
   PubMed Web of Science ®Google Scholar
• Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62
   PubMed Web of Science ®Google Scholar
• Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004;32:179-87
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8
   PubMed Web of Science ®Google Scholar
• Ghaffari S, Kitidis C, Zhao W, et al. AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation. Blood 2006;107:1888-91
   PubMed Web of Science ®Google Scholar
• Grimwade LF, Happerfield L, Tristram C, et al. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. Br J Haematol 2009;147:495-506
   PubMed Web of Science ®Google Scholar
• Bogani C, Bartalucci N, Martinelli S, et al. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. PLoS One 2013;8:e54826
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109-17
   PubMed Web of Science ®Google Scholar
• Verstovsek S KH, Pardanani AD, Thomas D, et al. The JAK inhibitor INCB018424 demonstrates durable and marked clinical reponses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post-PV/ET-MF). Blood 2008;112(Suppl)):abstract 1762
   Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015;372:426-35
   PubMed Web of Science ®Google Scholar
• Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047-53
   PubMed Web of Science ®Google Scholar
• Hagop K, Kiladjian J-J, Gotlib J, et al. A Pooled Overall Survival Analysis of The COMFORT Studies: 2 Randomized Phase 3 Trials of Ruxolitinib For The Treatment of Myelofibrosis. Blood 2013;122:2820
   Web of Science ®Google Scholar
• Kvasnicka H, Thiele J, Bueso-Ramos CE, et al. Effects Of Five-Years Of Ruxolitinib Therapy On Bone Marrow Morphology In Patients With Myelofibrosis and Comparison With Best Available Therapy. Blood 2013;122:4055
   Google Scholar
• Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013;27:1322-7
   PubMed Web of Science ®Google Scholar
• Pardanani AGG, Lasho TL, Hogan W, et al. A Phase I/II study of CYT387, an oral JAK-1/2 Inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. Blood 2010;116(Suppl):abstract 460
   Google Scholar
• Abdelrahman RA, Begna K, Al-Kali A, et al. Momelotinib treatment-associated neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. Br J Haematol 2015;169(1):77-80
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Seymour JF, Roberts AW, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood 2015;125(17):2649-55
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Dean JP, Cernohous P, et al. Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/µl. Blood 2013;122:395
   Web of Science ®Google Scholar
• Mascarenhas J, Lu M, Li T, et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol 2013;161:68-75
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Mesa RA, Fiskus W, et al. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol 2013;162:326-35
   PubMed Web of Science ®Google Scholar
• Kiladjian J-J, Heidel FH, Vannucchi AM, et al. Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis. 56th ASH® Annual Meeting and Exposition; 6-9 December 2014; San Francisco CA; 2014
   Google Scholar
• Andersen CL, Mortensen NB, Klausen TW, et al. A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis. Haematologica 2014;99:e5-7
   PubMed Web of Science ®Google Scholar
• Guerini V, Barbui V, Spinelli O, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008;22:740-7
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010;150:446-55
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 2008;22:965-70
   PubMed Web of Science ®Google Scholar
• Mesa RA, Verstovsek S, Rivera C, et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 2009;23:180-2
   PubMed Web of Science ®Google Scholar
• Odenike O, Godwin J, Besien K, et al. Phase II Trial of low dose, subcutaneous decitabine in myelofibrosis. Blood (ASH Annual Meeting Abstracts)2010: 2010 Abstract 2809 2809
   Google Scholar
• Jamieson C, Cortes JE, Oehler V, et al. Phase I dose-escalation study of PF-04449913, an oral Hedgehog (Hh) inhibitor, in patients with select hematologic malignancies [abstract 2804]. Blood (ASH Annual Meeting Abstracts) 2010;2011:118
   Google Scholar
• Gupta V, Koschmieder S, Harrison CN, et al. Phase 1b dose-escalation study of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis. 56th ASH® Annual Meeting and Exposition, San Francisco CA, 6-9 December 2014; 2014
   Google Scholar
• Fiskus W, Verstovsek S, Manshouri T, et al. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin Cancer Res 2011;17:7347-58
   PubMed Web of Science ®Google Scholar
• Baerlocher G, Leibundgut E, Ayran C, et al. Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results. Blood ASH Annual Meeting 2012. 179
   Google Scholar
• Tefferi A, LaPlant B, Benga K, et al. Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study. Blood ASH Annual Meeting 2014. 634
   Google Scholar
• Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011;118:2069-76
   PubMed Web of Science ®Google Scholar
• Pardanini A, Harrison CN, Cortes JE, et al. Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF). Blood 2013;122:393
   Google Scholar
• Harrison CN, Schaap NP, Zweegman S, et al. Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2). Blood 2013;122:661
   Google Scholar
• Zhang Q, Zhang Y, Diamond S, et al. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke’s encephalopathy. Drug Metab Dispos 2014;42:1656-62
   PubMed Web of Science ®Google Scholar